The status of liver transplantation for hepatitis C

Andrew M. Cameron, Ronald W. Busuttil

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


The hepatitis C virus (HCV) infects 3% of the world's population, or ∼170 million people. Most of those acutely infected progress to chronic infection and are unresponsive to existing antiviral treatment. Over a 20-year period, chronic HCV infection leads to cirrhosis and the sequelae of end-stage liver disease, including hepatic encephalopathy, ascites, variceal haemorrhage and hepatocellular carcinoma. Orthotopic liver transplantation (OLT) is the optimal treatment for decompensated HCV cirrhosis, but is limited by organ availability and universal graft reinfection. This review discusses the results with OLT for HCV from the Dumont-UCLA Liver Transplant Center and discusses future directions in the management of HCV.

Original languageEnglish (US)
Pages (from-to)993-1002
Number of pages10
JournalExpert Opinion on Biological Therapy
Issue number10
StatePublished - Oct 2006


  • Hepatitis C virus
  • Hepatocellular carcinoma
  • Orthoropic liver transplantation

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'The status of liver transplantation for hepatitis C'. Together they form a unique fingerprint.

Cite this